Transcription, Epigenetics and Ameliorative Strategies in Huntington’s Disease: a Genome-Wide Perspective by unknown
Transcription, Epigenetics and Ameliorative Strategies
in Huntington’s Disease: a Genome-Wide Perspective
Luis M. Valor
Received: 17 February 2014 /Accepted: 11 April 2014 /Published online: 1 May 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Transcriptional dysregulation in Huntington’s dis-
ease (HD) is an early event that shapes the brain transcriptome
by both the depletion and ectopic activation of gene products
that eventually affect survival and neuronal functions. Disrup-
tion in the activity of gene expression regulators, such as
transcription factors, chromatin-remodeling proteins, and non-
coding RNAs, accounts for the expression changes observed
in multiple animal and cellular models of HD and in samples
from patients. Here, I review the recent advances in the study
of HD transcriptional dysregulation and its causes to finally
discuss the possible implications in ameliorative strategies
from a genome-wide perspective. To date, the use of
genome-wide approaches, predominantly based on microar-
ray platforms, has been successful in providing an extensive
catalog of differentially regulated genes, including biomarkers
aimed at monitoring the progress of the pathology. Although
still incipient, the introduction of combined next-generation
sequencing techniques is enhancing our comprehension of the
mechanisms underlying altered transcriptional dysregulation
in HD by providing the first genomic landscapes associated
with epigenetics and the occupancy of transcription factors. In
addition, the use of genome-wide approaches is becoming
more and more necessary to evaluate the efficacy and safety
of ameliorative strategies and to identify novel mechanisms of
amelioration that may help in the improvement of current
preclinical therapeutics. Finally, the major conclusions obtain-
ed from HD transcriptomics studies have the potential to be
extrapolated to other neurodegenerative disorders.
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Introduction
Huntington’s disease (HD) is the most common
polyglutamine (polyQ) disorder, with a prevalence of 5–10
cases per 100,000 persons worldwide. In the classical variant,
pathology onset occurs in mid adulthood (approximately 30–
40 years old) and ends with the patient’s death, normally after
10–15 years. HD is characterized by personality changes and
psychiatric symptoms (e.g., affective disorders, suicide ten-
dency, mania, apathy, and schizophrenia-like symptoms), cog-
nitive deficits (e.g., poor planning and judgment, attention
problems, andmotor skill learning deficits), motor impairment
(e.g., chorea, gait abnormalities, bradykinesia, and rigidity),
sleep disturbance, and weight loss [1]. The basal ganglia and,
in particular, the striatum, wherein the GABAergic medium
spiny neurons (MSN) are especially sensitive, generally show
an early marked degeneration that extends to other brain areas
in later stages of the disease [1].
Conversely to more common neurodegenerative disorders,
such as Alzheimer’s (AD) and Parkinson’s (PD) diseases, the
cause of HD for all the patients is known: an aberrant expan-
sion of the polymorphic trinucleotide sequence CAG (in the
range of 37–121 repeats) at the N-terminus of the huntingtin
(Htt) protein. Whereas the number of repeats is strongly
correlated with the age of disease onset, additional genetic
variants may contribute to the differential manifestation of the
cognitive and motor symptomatology among patients [2]. In
any case, the mutation has two different consequences [3]: (i)
a loss-of-function effect, as one allele is no longer available for
the physiological roles of normal Htt such as vesicle traffick-
ing and synaptic transmission, and (ii) a gain-of-function
effect, characterized by the presence of a misfolded mutant
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Htt (mHtt) that interferes with multiple intracellular activities
through aberrant interactions and accumulates in aggregates,
mainly in the cell nucleus and neuropil. Overall, these com-
bined effects alter several cellular processes, such as protein
degradation, mitochondrial respiration and transcription
among many others, eventually leading to neuronal malfunc-
tion and cell loss.
Initial reports during the 1980s and 1990s demonstrated
selective altered expression of highly identifiable neuronal
genes, such as neurotransmitter receptors and neuropeptides,
first in patients’ brains and later in animal models [4–7]. The
importance of transcriptional dysregulation in the pathology
of HD was demonstrated by nuclear-restricted variants of
mHtt transgenes that reproduced part of the HD symptomatol-
ogy [8, 9]. With the advent of genome-wide approaches,
transcriptomics was soon adopted to extend the catalog of
affected transcripts in HD and to identify the most compro-
mised cellular processes due to the detrimental supply of key
components from the nucleus. However, the transcriptome is
not limited to protein-coding genes, which represent less than
5 % of the genome, and new classes of noncoding RNAs are
currently in the spotlight. The continuous development of
transcriptomics technologies and concurrent bioinformatic
tools is increasingly enlarging our global perspective of the
transcriptional phenomenon. Currently, deep sequencing tech-
niques coexist with newly improved array platforms to max-
imize coverage of the entire transcriptome, including noncod-
ing genomic features and alternative isoforms, and to connect
transcriptomics with other sources of genome-wide data relat-
ed to DNA modification and the occupancy of DNA-binding
proteins (histones and transcription factors). In this review, I
discuss the role of transcriptional dysregulation in the pathol-
ogy of HD and the postulated causes for this impairment, with
special emphasis on the information generated by high-
throughput techniques, as they have the potential to provide
a nearly complete vision of the genome regulation in response
to pathology and restorative strategies.
Widespread Transcriptional Dysregulation
in Huntington’s Disease
A long list of gene expression datasets have been generated in
less than 15 years of research on multiple HD animal and
cellular models and, importantly, on postmortem material
from patients (Fig. 1). The preferred system for the analysis
of HD transcriptomics has been microarray technology, with
some studies using alternative approaches, such as differential
display transcription [10, 11], to capture novel changing genes
not represented by the arrays at the time, or systematic qPCR-
based assays [12–15], to selectively interrogate specific sub-
sets of genes with high sensitivity as in the case ofmicroRNAs
(miRNAs), prior to the use of dedicated microarrays and deep
sequencing technologies [16–19]. The results obtained using
the most novel RNA-seq approach are consistent with
microarray-based profiles [16, 20, 21], with the added benefit
that they analyze the behavior of poorly characterized gene
products, such as variants of mature miRNA or isomiRs [16].
An overview of the major conclusions derived from HD
transcriptomics is given below.
Transcriptional Dysregulation Is an Early and Progressive
Event
Profiling studies in HD animal models usually explore a
minimally symptomatic stage at the phenotypical and mor-
phological level that, in contrast, show a substantially
disrupted transcriptome that worsens during progression of
the disease [17, 22–30]. Further demonstrations of the prema-
turity of transcriptional alterations have been provided by
highly controlled in vitro preparations in which gene expres-
sion changes occur prior to cell loss, mHtt aggregation, or
mitochondrial dysfunction [12, 15, 31–35]. Additionally,
evidence for transcriptional alterations was provided by
the laser capture microdissection (LCM) of intact neurons
from early symptomatic brain samples, which yielded a
transcriptional profile largely comparable to that obtained
from whole homogenates [36], indicating that a significant
component of the HD signature in tissues is not derived
from neuronal loss.
However, transcriptional dysregulation is not too early
on time [23, 33, 37, 38], and accumulation of events are
seemingly needed (e.g., mHtt concentration and nuclear
shuttling) to overtly affect regulatory mechanisms. In any
case, the progression of gene expression and phenotype
can be correlated, as demonstrated by the identification of
genes associated with performance impairment in the
rotarod task and in decreased exploratory and spontaneous
activities [39].
Transcriptional Dysregulation Affects Relevant Genes
for Brain Function
Diverse processes are usually represented in HD transcription-
al profiles: downregulation is generally associated with genes
involved in signaling pathways (e.g., dependent on cyclic
nucleotides and trophic factors), neurotransmitter receptor
and ion channel functions (e.g., dopamine, serotonin, adeno-
sine, GABA, and glutamate receptors), neuropeptides (e.g.,
proenkephalin and somatostatin), synaptic transmission (an-
choring and vesicle components), and calcium binding and
homeostasis, whereas upregulation is generally associated
with genes related with RNA metabolism, protein folding,
and stress markers. Expression of transcription and chromatin
remodeling factors can be altered in either direction. A more
exhaustive discussion of the biological implications of
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deregulated genes in the context of HD can be found in the
excellent reviews by Cha [40] and Seredenina and Luthi-
Carter [41]. Functional information can be obtained from
transcriptomics studies that not only provides potential caus-
ative contributors for perturbed cellular processes but also
highlights other aspects of the molecular dysfunctions that
otherwise may have been overviewed. Next, some few exam-
ples are discussed to illustrate the utility of HD transcriptomics
for the proposal of new research lines:
1. The relevance of intracellular signaling pathways. The
first transcriptomics studies soon demonstrated impair-
ment of signaling cascades, as in the case of
cAMP/PKA-dependent signaling pathway. Thus, tran-
scriptional dysregulation of diverse adenylyl cyclases,
which promote cAMP synthesis, was concomitant to a
reduction in the binding of their activator forskolin in HD
mouse striata [22]. Moreover, stimulation of the cAMP
pathway was beneficial for a HD cellular model [15], in
which the activity of the downstream transcription factor
cAMP-responsive element binding protein (CREB) was
decreased. These observations have led to the study of
CREB involvement in HD [42, 43] and to the use of
phosphodiesterase inhibitors, which prevent degradation
of cyclic nucleotides, as potential therapeutical means [44,
45]. The importance of disrupted intracellular signal trans-
duction is further confirmed by the emergence of com-
pensatory mechanisms to restrain the deleterious effects
of altered cascades. This is the case for some G protein
regulators (RASD family, member 2/Ras homolog
enriched in striatum (Rasd2/Rhes), RAS guanyl-
releasing protein 2/calcium and DAG-regulated guanine
nucleotide exchange factor I (Rasgrp2/CalDEG-GEF1),
and regulator of G protein signaling 2 (Rgs2)) which
actively contribute to the mHtt-induced toxicity and are
downregulated at the transcript level in HD (reviewed in
Seredenina and Luthi-Carter [41]). Further inhibition of
this type of signaling components may constitute promis-
ing therapeutical strategies.
2. Impairment of cholesterol homeostasis. Research investi-
gating the involvement of cholesterol in HD was boosted
by a microarray study of a HD-inducible striatal cell line
in which genes related to lipid metabolism and cholesterol
biosynthesis were found to be downregulated [31]. There-
after, imbalance in the levels of cholesterol and related
metabolites has been found in different HDmodels and in
patients, proportional to the length of CAG expansion.
This imbalance has been documented as a decrease in
brain, plasma, or cultured fibroblasts, although with some
examples of cholesterol accumulation (reviewed in
Valenza and Cattaneo [46] and Leoni and Caccia [47]).
Brain cholesterol is primarily found as a constituent of the
myelin, followed by astrocytes and neurons, and partici-
pates in myelination, neurite outgrowth promotion, for-
mation and maintenance of the synapses, integrity of the
membrane microenvironment for neuronal channels and
receptors, and vesicle transport and exocytosis. Therefore,
impairment of the cholesterol homeostasis may have a
relevant impact in neuronal signal transduction and vesi-
cle trafficking in HD.
Fig. 1 Summary of the gene profiling and other genome-wide studies in
HD. The graph represents the number of studies per publication year with
the most relevant milestones in the field of HD transcriptional dysregu-
lation. Note that a few studies may contain more than one approach,
categorized as “Array” (expression and ChIP-on-chip), “NGS” (next-
generation sequencing, RNA-seq, ChIP-seq, sequencing of methylated
DNA) and “Others” (PCR-based: differential display, adapter-tagged
competitive PCR, panels). Reports with solely reanalysis (i.e., without
generating data de novo) or chemically lesioned striatal models are not
considered. References per year: 2000, [22]; 2001, [10, 15]; 2002: [12,
23, 24, 31, 65]; 2003, [173, 193]; 2004, [11]; 2005, [9, 25, 51, 135, 159,
194]; 2006, [26, 34, 36, 37, 157, 195]; 2007, [32, 38, 52, 54, 72, 110, 133,
154, 196]; 2008, [13, 27, 33, 39, 56, 103, 125, 155]; 2009, [35, 151, 152,
197]; 2010, [14, 16, 158, 165, 174, 192]; 2011, [18, 19, 30, 50, 57, 67,
119, 127, 156, 198]; 2012, [17, 66, 99, 111, 112, 181, 199]; 2013, [20, 21,
28, 29, 49, 53, 68, 113, 116, 124, 128, 180, 200]
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Transcriptional Dysregulation Is Not Exclusive to the Brain
HD mouse models in which the mHtt transgene was designed
to reproduce the ubiquitous expression pattern of the endog-
enous Htt [48] show altered transcriptomes in the retina [26]
and in nonneuronal tissues, such as blood [49] and muscle [23,
25], in the latter case with apparently little contributions of
diabetes and weight loss. Peripheral tissues facilitate access to
biomaterial and open the possibility of their use in the identi-
fication of biomarkers. Transcriptomics can determine in an
unbiased manner the expression changes associated with the
disease in blood samples [19, 50–52] and skin fibroblasts from
patients [53]. Indeed, late and early presymptomatic stages
have distinctive profiles [51], further supporting the suitability
of peripheral expression changes for measuring pathology
progression.
HD Transcriptional Signatures Are a Complex Mixture
of Common and Specific Changes
To date, the best attempt to meta-analyze striatal profiles from
different animal models (including knock-in and transgenic
mice for different mHtt lengths) within the same study [38]
revealed a high degree of concordance, although a definitive
description of a consensus core HD signature is still lacking.
Importantly, animal models are able to recapitulate relevant
features of the transcriptional dysregulation associated with
HD in patients [27, 36, 38, 54–57]. Common changes were also
observed among different brain areas and in nonneuronal tissues
[18, 23, 25, 28, 36] and more strikingly among different polyQ
disorders (see “Final Remarks” section), despite the apparent
overrepresentation of regional and model-specific changes.
The presence of specific changes is the result of several
factors as discussed below:
1. Intrinsic properties of the tissues, such as sensitivity to
degeneration and tissular-specific transcription. The stria-
tum exhibits a special sensitivity to neurodegeneration, as
demonstrated by general insults that severely affect
striatal cells, such as hypoxia, hypoglycemia, and ische-
mia [58], systemic administration of neurotoxins (e.g., 3-
nitropropionic acid (3-NP) and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)) [59, 60], and somatic
CAG instability of the Htt gene [61]. This latter suscepti-
bility is correlated with the acceleration of the pathology
and can be predicted at the transcriptome level in different
tissues [62, 63]. Therefore, the striatum and, in particular,
the caudate nucleus are the brain areas that show greater
transcriptional dysregulation compared with cortical areas
and the cerebellum, in accordance with the earliest and
more severe manifestations of the disease in humans [36].
Moreover, in the striatal region, the profile may be pro-
nouncedly distorted by a cell population shift (i.e.,
neuronal loss concomitant with glial activation). The ef-
fect of tissular-specific transcription is observed by the
fact that striatal-enriched genes are generally more sensi-
tive to dysregulation within the striatum [37] and also by
the normal differential gene regulation across brain areas:
genes with differential levels of expression tend to appear
in the tissular-specific HD signature, whereas genes with
similar expression levels tend to be part of nonspecific
pathways that become altered in HD [30]. Whether this
dichotomy is in concordance with specific and common
transcriptional regulators remains to be fully determined.
2. Intrinsic properties of the models. For example, the pro-
moter sequences driving transgene expression (e.g., ubiq-
uitous vs neuronal-restricted) determine which cell types
will be more affected, and the length of the mHtt deter-
mines the progression rate of the disease because N-
terminal transgenes lack the required signals present in
full-length mHtt (either transgenic or knock-in) to pro-
mote degradation in response to misfolding [64]. Gene
profiles of fast and slow progressive models were initially
described as not reproducible [65] mainly because they
were retrieved from dissimilar stages of the pathology;
once these models were comparable, the gene profiles
were significantly similar [38]. The number of CAG
repeats is also relevant, as initially suggested by transgen-
ic models [33, 66] and as further confirmed in heterozy-
gous knock-in systems with descriptions of a relatively
consistent and prominent transcriptional signature associ-
ated with an increasing length of repeats [67, 68].
3. Analytical procedures. The intrinsic properties discussed
above make performing a reliable meta-analysis of dis-
tinct gene profiles difficult; this limitation is more evident
if based on the results of conventional pair-wise compar-
isons between the control and the aberrant Htt expansion
situations using arbitrary thresholds. Exploring alternative
approaches has led to interesting insights that otherwise
would have remained undetected: for example, the afore-
mentioned accumulative dysregulation associated with
CAG repeats, the detection of subthreshold HD signatures
in a less affected brain area [30], and the dissection of the
relative contribution of cell populations to the HD tran-
scriptional signature in heterogeneous tissues [69]. In the
case of biomarkers, investigation of a natural human
population characterized by confounding demographic
and individual factors is challenging from an analytical
point of view. A first study reported 12 promising candi-
dates from the blood of human patients [51], which were
not confirmed by other studies [50, 52], even with the
reanalysis of the original data [70]. However, the collec-
tion of proposed biomarkers in these studies were to some
extent reproduced in independent cohorts, indicating that
integrative analytical procedures are required to reach a
reliable consensus.
Mol Neurobiol (2015) 51:406–423 409
HD Is Not Fully Explained by Mitochondrial Dysfunction
Mitochondrial dysfunction is supported by several pieces of
evidence: the mitochondrial localization of mHtt, the defective
Ca2+ homeostasis, the impairment of mitochondrial respiration
and trafficking in mHtt-expressing cells, and the reduced activ-
ity of peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α), which is relevant for the expression
of genes related to mitochondrial biogenesis and oxidative
phosphorylation [71]. 3-Nitropropionic acid (3-NP) irreversibly
inhibits succinate dehydrogenase, the enzymatic activity re-
quired for the mitochondrial electron transport chain, and in-
duces striatal neuronal degeneration and a HD-resembling phe-
notype [60]; thus, 3-NP treatment is regarded as a chemical-
inducible model of HD. However, striatal gene profiling dem-
onstrated a lack of correlation between mHtt-expressing and 3-
NP-treated animals [18, 55] and immortalized cell lines [72].
This is in agreement with the comparison with PGC-1α knock-
out profile (see “PGC-1α” section). Overall, energy deficiency
in HD is not fully explained by mitochondrial dysfunction, and
extramitochondrial mechanisms should be investigated.
Multiple Gene Expression Regulators Are Altered
in Huntington’s Disease
Among the gene expression regulators, we can find transcrip-
tion factors and associated cofactors, including chromatin-
remodeling proteins and noncoding RNAs (ncRNA).
Chromatin-remodeling proteins are gaining increasing interest
in neuropathology as they are responsible for the epigenetic
deficits observed in mental and neurological disorders [73,
74]. Research in HD and other polyQ disorders introduced
epigenetics and epigenetic-based correctives early in the last
decade, and these studies were soon extended to more com-
mon neurodegenerative disorders, such as AD. This led to the
general hypothesis of epigenetic imbalance as one of the most
important causes of the altered expression of genes involved
in neuronal function and survival in neurodegenerative pro-
cesses [75]. Since then, several modifications of histones
(acetylation, methylation, ubiquitylation, and phosphoryla-
tion) and DNA (methylation and hydroxymethylation) have
been described to be affected in HD (for further details, see
Valor and Guiretti [76]). Regarding ncRNAs, microRNAs
(miRNAs) have been extensively examined in the context of
this polyQ pathology and in other neurodegenerative disor-
ders [77]. miRNAs exert posttranscriptional inhibition by
halting translation or by promoting RNA degradation [78],
in the latter case consequently modulating the net transcript
level of a given gene. As mentioned previously, several
miRNAs are deregulated in HD, and in some cases, their
potential target transcripts are found to be changed in the
opposite direction [13, 14, 79]. Very recently, the involvement
of a new class of ncRNAs, small CAG-repeated RNAs
(sCAG-RNAs), has been described in HD. sCAG-RNAs are
derived from the mHtt transcript and promote the degradation
of messenger RNAs (mRNAs) containing CUG-rich se-
quences, with deleterious consequences [80], thus demon-
strating that bothmHtt protein and RNA can contribute to HD.
Mechanisms for Disruption of Gene Expression Regulators
The activity of gene expression regulators can be affected in
several ways, as defined in single-gene studies:
1. By a loss of interaction with wild-type Htt. The best-
known example is the RE1-silencing transcription
factor/neuron-restrictive silencer factor (REST/NRSF)
that is physiologically retained by wild-type Htt in the
cytoplasm. Thus, loss of a single allele promotes the
nuclear translocation of this factor and alters the expres-
sion of neuronal genes [81], as discussed in the next
section. Other examples are nuclear factor kappa B
(NF-κB), which is translocated from dendrites to the
nucleus through the interaction with wild-type Htt [82],
and nuclear receptors [83], including liver X receptor
(LXR), a key regulator of cholesterol metabolism [46,
47].
2. By aberrant interactions with mHtt. This is the best-
characterized action and was originally proposed because
several transcription regulators, such as the acetyltrans-
ferase CREB-binding protein (CBP), the histone
deacetylase complex subunit mSin3a, the tumor suppres-
sor p53, the transcription elongation regulator 1 (Tcerg1/
CA150), and the TATA-binding protein (TBP), among
many others [84–88], were found within the mHtt aggre-
gates, suggesting a depletion of regulatory factors needed
to maintain normal levels of expression. Other evidences
further support mHtt-dependent transcription failure. For
example, the expression of exogenous mHtt produces
cell-autonomous transcriptional dysregulation, as docu-
mented by transcriptomics studies [12, 15, 33, 34], and
alters in vitro reporter expression [15, 84, 89–91]. Addi-
tionally, there is a CAG repeat-dependent transcriptional
response in the context of both loss- and gain-of-function,
as previously mentioned. However, the pathogenic role of
mHtt aggregates is still under debate, and recent evidence
favors soluble mHtt as the toxic form responsible for the
molecular failures observed in the pathology [92–95].
Regarding transcription, aggregative inclusions of mHtt
did not significantly decrease or change the nuclear dis-
tribution of some transcriptional regulators [90, 96, 97],
and soluble forms of mHtt were able to inhibit their
activities per se [98–101], as occurs in the case of the
housekeeping specificity protein 1 (Sp1), CBP, and TBP.
In agreement with these observations, altered gene
410 Mol Neurobiol (2015) 51:406–423
expression can appear prior to nuclear Htt aggregation as
already discussed [31, 100, 102]. Finally, interference by
mHtt can also occur at the promoter level through direct
association with DNA [103, 104].
3. By the disruption of upstream gene expression regulators.
Apart from miRNAs, transcription factors and associated
cofactors can also be prominently deregulated at the tran-
script level, as retrieved by functional enrichment analy-
ses of pathological gene profiles. Nonetheless, such dys-
regulation does not always contribute to the progression
of the disease by affecting downstream target genes, but it
can also be a part of the homeostatic response in an
attempt to restore lost activities. An example is the
CCAAT-binding protein nuclear factor Y (NF-Y) that is
present in mHtt aggregates with a concomitant reduction
in protein levels but upregulated at the mRNA level [105].
4. By abnormal protein degradation, by either promoting or
preventing the removal of regulators such as CBP [76] or
the Wnt-dependent transcriptional coactivator β-catenin
[106], respectively.
Genome-Wide Approaches to Link Transcriptional
Dysregulation and Altered Regulator Activities
To gain further insight on the regulatory mechanisms respon-
sible for HD signatures, gene expression datasets can be
analyzed for the enrichment of transcription factor binding
sites (TFBS) to infer the most promising factors involved in
the transcriptional deficits. Along the same lines, the 3′UTRs
of deregulated genes can be scanned for the putative binding
of miRNAs. Early attempts, although limited by the scarce
knowledge of genomic sequences at the time, were able to
identify a small subset of deregulated genes with DNA motifs
at their promoters for Sp1 [23] and CREB [15], the latter being
implicated in neurodegenerative disorders [107]. Some recent
reports have predicted the enrichment of more representative
binding motifs in large datasets, such as the sequences for
NF-κB, Sp1, p53, REST, the procaspase activator HIP1 pro-
tein interactor (HIPPI), or miR-22 [14, 16, 20, 21, 28, 72, 108,
109], to cite some examples.
There are, however, obvious limitations to the prediction
strategy. First, regulatory proteins are able to bind through
noncanonical consensus sequences or indirectly through the
recruitment of other associated factors; second, the use of
predicted DNA motifs may depend on the tissue-specific
context, i.e., on the presence of specific cofactors and
interacting partners; and third, this strategy is not valid for
chromatin-remodeling proteins, as they do not recognize any
primary sequence in the DNA. Finally, predictions are highly
dependent on the assumptions made by the algorithms, which
can be especially problematic in the case of miRNA-binding
sequences. Two different approaches circumvent these issues:
(i) meta-analysis of gene profiles to determine the degree of
similarity between the HD signature and the transcriptional
changes caused by genetic manipulation of particular regula-
tors [66, 104] and (ii) mapping the genomic occupancy of
nuclear proteins. This second approach offers an important
advantage over the former one: both direct and indirect targets
are distinguishable, without the confounding homeostatic re-
sponse that may be highly specific for a particular genetically
engineered model. In the HD field, initial efforts exploited
array platforms to examine the DNA positions originally
bound to the protein of interest after immunoprecipitation with
a specific antibody in the so-called ChIP-on-chip approach
[103, 110, 111]. As occurs with transcriptomics-based tech-
niques, this approach was not fully unbiased but restricted to
the probes spotted in the arrays, and usually the promoter
regions of known genes were interrogated without consider-
ing the regulatory regions distal to the transcription start site
(TSS), thus excluding enhancers and the promoters of undis-
covered genes and alternative isoforms from the analysis.
Currently, next-generation sequencing is the preferred ap-
proach to investigate genomic occupancy (ChIP-seq) [20,
21, 28, 66, 112, 113], as it enables nearly nucleosome resolu-
tion, allows the redefinition of the consensus DNA motif and
possible variants, and explores the contribution of neighbor-
ing sequences.
Next, studies designed to link transcriptomics with the
activity of particular expression regulators are discussed in
detail.
REST
REST is a Kruppel-type zinc finger protein that was originally
described as a repressor of neuronal genes in nonneuronal
cells for maintaining the phenotypic identity of these cells,
according to its high expression level in embryonic and
nonneuronal cells, opposed to the lower level observed in
neurons (reviewed in Adachi and Monteggia [114]). As pre-
viously commented, this repressor can enter the nucleus of
HD neurons and repress the expression of cortical transcripts,
such as brain-derived neurotrophic factor (BDNF) [81]. To
identify additional HD genes that are dysregulated because of
REST binding, chromatin lysates from patients with advanced
grade of disease were examined by a ChIP-on-chip approach
using an array specifically designed to explore canonical RE1/
NRSE sites in the human genome [110]. To minimize the use
of human material, it is possible to take advantage of the high
functionality of REST in proliferative cells and employ ChIP-
seq information derived from accessible cell lines to enlarge
the list of candidate genes for further examination in HD
signatures. In doing so, it was possible to identify the first
long noncoding RNAs (expressed in the locus of human
accelerated region 1 (HAR1)) as downregulated in the stria-
tum of HD patients [115] and to tightly associate direct REST
Mol Neurobiol (2015) 51:406–423 411
regulation with the decreased expression of miRNAs and
neuronal genes in a HD cell model [116].
Forkhead Box Protein 1 (Foxp1)
Foxp1 and other members of the subfamily play important
roles in cell-type-specific gene expression in the heart, lung,
t hymus , immune ce l l s , and deve lop ing b ra in .
Haploinsufficiency in humans may be the cause of an intel-
lectual disability that severely affects the onset of speech and
language and is also commonly associated with distinctive
facial features, autistic traits, and congenital malformations
[117]. Foxp1 shows high levels of expression in the striatum
and is downregulated in HD models and in the caudate nucle-
us from patients [37]. Genome-wide analysis of the involve-
ment of Foxp1 in HD transcriptional dysregulation has been
conducted in a series of concatenated experiments. First,
combined microarray and ChIP-seq analysis in a striatal cell
line overexpressing this transcription factor identified a set of
bona fide target genes, including some associated with inflam-
matory and immunological disorders in other systems [66]. In
agreement with the in vitro results, viral transduction of Foxp1
primarily led to the repression of immune-related genes in the
adult striatum. This pattern moderately anticorrelated with
published HD transcriptional signatures of animal models
and patients [66]. Although this study suggested an interaction
with mHtt, it is not clear whether the Foxp1 actions in glial
cells are direct, because the main transduced cells in the
in vivo experiments were neurons, and endogenous Foxp1
binding has not been examined in a symptomatic scenario. In
any case, modulation of Foxp1 activity offers a potential new
strategy to ameliorate the polyQ pathology by restricting
astrocytic and microglial activation in HD.
Heat Shock Factor 1 (HSF1)
HSF1 is a leucine zipper transcription factor and a key regu-
lator of the heat shock proteins (HSPs), including chaperones
involved in protein homeostasis (folding, degradation,
targeting, etc.), the expression of which is induced in response
to different types of stress. In fact, some reports demonstrated
an altered gene expression pattern for some of these proteins
[32, 105, 118], and ameliorative strategies aimed at enhancing
either HSP or HSF1 activities have been proposed to be
beneficial in HD (see “Transcriptomics-Based Ameliorative
Strategies” section). To understand the potential role of HSF1
in HD, a ChIP-seq analysis was conducted in the mHtt-
expressing immortalized striatal cell line STHdhQ111/Q111
[112]. In the basal state, relatively few loci were bound by
HSF1 in this cell line, and the majority of these loci (~75 %)
were the same as in the control STHdhQ7/Q7 cells. However,
under heat shock conditions, HSF1 showed increased geno-
mic binding in the control cell line that was impaired under the
expression of the expanded polyQ version and affected more
than one third of HSF1-dependent genes. Whereas
proteostatic genes were enriched in the HSF1-associated sig-
nature in the two cell lines, genes showing deficits in both
gene expression and HSF1 binding in the mutant condition
were represented by other unrelated functions, suggesting that
the response to HSF1-induced stress is largely preserved in
this HD model. However, this situation is more complex
in vivo [119], as we will see in brief. In any case, a significant
number of HSF1 targets were found in the HD signature of
animal models and patients, pinpointing the potential rele-
vance of HSF1-dependent transcription in the pathology
[112].
PGC-1α
PGC-1α is a transcriptional coactivator that regulates the
expression of mitochondrial genes among other targets. Its
potential relevance in HD has been suggested by a specific
decrease in PGC-1α in the postmortem caudate nucleus of HD
patients, a similar motor phenotype in PGC-1α knockout and
HD mice that is worsened when combining both mutations
and by the fact that overexpression experiments restoring
PGC-1α levels ameliorated neurodegeneration and mHtt ag-
gregation [104, 120]. In the seminal study by Krainc and
coworkers [104], microarray analysis of knockout mice re-
vealed deregulated genes involved in oxidative phosphoryla-
tion, mitochondrial function, and the electron transport chain.
These pathways were also altered in HD patient profiles [36].
However, a deeper comparison with HD datasets did not show
a significant transcriptome-wide overlap [55, 120], indicating
that disruptions of mitochondrial pathways are not sufficient
to elicit the widespread transcriptional response reported in
HD, in agreement with the observation made with chemically
induced mitochondrial dysfunction (see “HD Is Not Fully
Explained by Mitochondrial Dysfunction” section).
Epigenetic Marks and Associated Proteins
Epigenetic marks that are linked to physiological processes,
such as memory formation, and to intellectual disabilities and
aging [121–123] have been investigated in a genome-wide
manner in HD. These marks include those that are associated
with active genes (H3K9/14 ac and H4K12ac in the promoters
and adjacent regions of the R6/2 striatum [111] and in the
nonrepetitive genome of the N171-82Q hippocampus [28]
and H3K4me3 in the R6/2 cortex and striatum [21]) and with
repressed genes (H3K9me3 [113] and DNA methylation [20]
in STHdhQ111/Q111 and control STHdhQ7/Q7 cells). How-
ever, in the latter case, 5-methylcytosine (5-mC) and 5-
hydroxymethylcytosine (5-hmC) were in principle not distin-
guishable. 5-mhC is highly enriched in neurons and may
constitute an intermediate step in demethylation, leading to
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gene derepression [76]. The genomic pattern of this modifi-
cation has been determined and shows a general reduction in
the presymptomatic cortex and striatum of YAC128 mice
[124]. Interestingly, changes in the local levels of 5-hmC
correspond to changes in expression in the same direction
for selected genes, suggesting a positive association with gene
activation that is altered in HD.
Surprisingly, the genome-wide correlation between differen-
tial histone acetylation and gene expression is poor, despite
observance of a net hypoacetylation [28, 111]. Methylation of
either histones or DNA appears to be more correlated [20, 21,
113], most likely reflecting a distinct biological relevance for
epigenetic marks in HD. Alternatively, it is tentative to specu-
late that the use of the same deep sequencing-based technology
to map either gene expression or epigenetic marks may allow
better data integration for comparative purposes. Even in these
studies, the correlation is not globally consistent, as it is possi-
ble to find a high proportion of genes with no correlation or
with a correlation opposite to expectations. At least three pos-
sibilities may explain these discrepancies: (i) additional regula-
tory mechanisms are required to totally connect transcriptional
and epigenetic dysregulation (see “Toward an IntegrativeMod-
el of HD Transcriptional Dysregulation” section), (ii) homeo-
static responses may emerge in a locus-specific basis to even-
tually restore expression by alternative means, and (iii) epige-
netic modifications may have differential roles or repercussions
in transcript regulation depending on the genomic location. In
this sense, a general theme emerges that the altered epigenetics
at TSS and the surrounding regions are more prone to be
correlated with altered expression in HD, thus affecting genes
with primary roles in synaptic transmission, cytoskeleton-
dependent processes, and signal transduction [20, 21, 28,
113]. In addition, broad islands of H3K4 methylation around
TSS in control animals are better predictors than the sharp
islands of downregulation observed in transgenic mice [21],
indicating that the shape of the binding profile somehow re-
flects specialized functions in gene regulation.
To complement these results, a genome-wide landscape of
chromatin-remodeling proteins is missing. At the moment, a
reduction of the hypomethylation of the H3K4 mark in HD
has been ascribed to the upregulation of the specific histone
demethylase lysine (K)-specific demethylase 5C (KDM5C/
SMCX/Jarid1c). This is supported by knockdown experi-
ments that reported an increase in the expression levels of
selected genes [21].
In the absence of nucleosome resolution, meta-analysis of
transcriptome data from different studies may provide key
insight. Histone deacetylation as a result of decreased acetyl-
transferase and increased deacetylase activities is present in
several polyQ models, although this latter finding needs further
clarification [76]. Anyway, general nonspecific deacetylase
inhibition leads to phenotypical amelioration (see “Transcripto-
mics-Based Ameliorative Strategies” section). Therefore,
identifying the relevant histone deacetylases (HDACs) in these
beneficial effects may help in the development of more specific
drugs. Studies in yeast revealed a significant overlap between
mHtt-induced downregulation [125] and the target genes iden-
tified to bind Rpd3 (the ortholog of HDAC3) in a separate ChIP
genomic mapping [126]. Interestingly, the yeast mutant for a
component of the Rpd3 complex, Ume1, suppresses mHtt-
induced toxicity [127]. In mice, the involvement of HDACs
is more complicated, as the knockdown of several isoforms in a
mHtt-expressing context did not have apparent beneficial ef-
fects [76]. The exception is HDAC4, the reduction of which
improved a series of faulty phenotypical, electrophysiological,
and biochemical properties without restoring the HD-
associated transcriptome [128]. However, marginal changes
such as the rescue of BDNF levels were observed. A parallel
study of HDAC4 knockout postnatal brain casts doubt on the
gene-repressive role of this protein, in contrast to the conclu-
sions obtained in the overexpression approach [129], because
the pattern of acetylation was not altered, and only minor
changes were observed at the level of the transcriptome [130].
A strong functional redundancy by other family members is an
alternative plausible explanation for these negative results.
Huntingtin
Interestingly, Htt can bind directly to DNA, as shown in
immortalized striatal cell lines and in brain tissue from R6/2
mice and patients, not only at the promoter level but also to
intronic and intergenic regions, including repetitive sequences
[103]. Because the cell lines were derived from homozygous
knock-in strains bearing different polyQ extensions, it was
feasible to compare the behavior of two different Htt versions
(bearing the normal and a pathological length of polyQ) at the
DNA binding level. Strikingly, they exhibited a distinct pat-
tern of genomic occupancy at the promoter level in a ChIP-on-
chip approach, with no correlation between Htt occupancy
and gene expression changes. Variants of recombinant Htt-
exon 1 were able to bind in vitro to multiple known DNA
motifs in a polyQ-dependent manner and change the confor-
mation of the DNA [103], suggesting that the effects of Htt
binding may involve a generic and most likely nonspecific
mechanism of interference and alteration of chromatin struc-
ture. The function of wild-type Htt in the nucleus deserves
further investigation, despite its low abundance in this com-
partment, as an early report suggested a scaffolding role for
multiprotein complexes in nuclear processes [131].
Toward an Integrative Model of HD Transcriptional
Dysregulation
A review of the vast literature together with a systematic
analysis of transcription factor activities as performed by
Cha and colleagues [103] leads to the conclusion that dozens
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of gene expression regulators are affected in HD. Although
the precise contribution of each regulator to the HD signature
remains to be determined with temporal and regional preci-
sion, it is reasonable to conclude that a few factors cannot be
responsible for the complex gene profiles observed in the
transcriptomics studies. Causal relationships are difficult to
tract, and homeostatic responses are intermixed with deleteri-
ous dysregulation [41].Moreover, our still limited understand-
ing of basic regulatory processes, such as those represented by
epigenetic mechanisms in neuronal gene expression, enhances
our handicap in determining the precise origin of HD tran-
scriptional dysregulation ([76], Lopez-Atalaya and Barco, in
preparation).
Integrating different regulatory mechanisms may provide a
more complete picture, as changes in expression levels may be
the result of disruption of convergent regulators (Fig. 2).
Transcription factors may shape epigenetics through the con-
trol of chromatin-remodeling protein expression, as in the case
of histone methylation. The reported global hypermethylation
of H3K9 in HD mouse models and in patients [132–135] has
been explained as a result of abnormal increase of binding
activity to the promoters of chromatin regulator genes: (i) the
binding of Sp1 and Sp3 to the promoter of the histone-lysine
N-methyltransferase SET (SU(VAR)3-9, enhancer of Zeste,
Trithorax) domain bifurcated 1 (SETDB1, also known as
ESET) [134] and (ii) the binding of caudal type homeobox 2
(Cdx2) to the promoter of the DNA-dependent ATPase/
helicase alpha thalassemia/mental retardation X-linked
(ATRX) [136]. Interestingly, it has been proposed that CBP
is an indirect repressor of SETDB1 [137], which reduction in
HD may also contribute to SETB1 upregulation. In another
example, REST appears to be a primary cause of miRNA
dysregulation in HD [138] that can also influence epigenetics.
In combination with the corepressors Sin3a/b and CoREST,
REST recruits multiple chromatin-remodeling complexes
containing histone methylases (G9a) and demethylases
(LSD1 and KDM5C), histone deacetylases (HDAC1 and
HDAC2), and the methyl–CpG-binding protein MeCP2,
among others. REST binding moderately correlates with de-
creased histone posttranslational modifications associated
with active genes and increased histone methylation associat-
ed with repression [138]. To be more precise, a decoy
oligodeoxynucleotide containing REST motifs was able to
remove REST from the promoters of downregulated genes
in mHtt-expressing striatal cell lines, with an increase in
K9H3ac levels and a reversal of expression deficits [139].
Finally, miR-9/miR-9* closes the circle by providing a feed-
back mechanism for its own REST-dependent transcriptional
decrease in HD as it regulates REST and CoREST expression
[13]. Although causality has not yet been well established, the
relationship between transcription factors and epigenetics has
been assessed at the genomic scale. In particular, altered
patterns of DNA methylation have been linked to the binding
of the transcription factor Fos-related antigen 2 (Fra-2), the
proto-oncogene JunD, and sex-determining region Y-box 2
(Sox2) [20]. Bisulfite sequencing of the DNA from the
STHdhQ111/Q111 and STHdhQ7/7 cell lines identified dif-
ferential patterns of cytosine methylation that were more
evident at CpG-poor regions. The primary focus was on low
methylated CpG-poor regions, as they could be potentially
created by transcription factor binding, as reported in embry-
onic stem cells [140]. While seeking candidates, Sox2 and the
Fig. 2 Convergent disruption of
regulatory mechanisms
for differentially expressed genes
in HD. Schematic representation
of a hypothetical deregulated
gene in HD, which transcriptional
dysregulation may be the result of
correlated changes in the complex
genomic redistribution and
occupancy of transcription
factors, epigenetic marks, and
miRNAs. SNPs, although
invariant, may contribute to the
susceptibility to the expression
change. Arrow, direction of the
gene; shade box, CpG island
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AP-1 members Fra-2 and JunD were further investigated, as
they were deregulated at the transcriptional level, and their
binding motifs were enriched in these regions. Confirming
expectations, ChIP-seq experiments showed a complete loss
of Sox2 in mHtt-expressing cells and a negative correlation
between changes in the binding of AP-1 factors and DNA
methylation, primarily in distal positions [20].
Another aspect to consider for integration is the fact that
histones and transcription factors can be posttranslationally
modified by the same enzymes. For example, mitogen- and
stress-activated kinase 1 (MSK-1) phosphorylates both his-
tone H3 and CREB [141], and CBP acetylates not only
histone tails but also transcription factors relevant to HD, such
as p53. The tumor suppressor factor p53 interacts with mHtt
[84] and can mediate the cytotoxicity and mitochondrial dys-
function initiated by mHtt [142]. More recently, p53 was
found to be hyperacetylated in HD models, in accordance
with a proapoptotic role [143], although mHtt expression
could also induce hypoacetylation at the same residue [144].
These apparently paradoxical results can be explained by the
complex pattern of p53 acetylation [145] because different
combinations of lysines become acetylated in response to
apoptosis and DNA damage or to the neuroprotective effect
triggered by pharmacological treatment [146]. Another example
of CBP-target protein is the RNA polymerase I factor upstream
binding factor 1 (UBF1), found to be depleted in both animal
and cellular HD models together with downstream ribosomal
precursor mRNA [147]. Overall, due to its multiple interactions,
CBP may act as a scaffolding and acetylation source for several
nuclear proteins within the same locus.
Transcriptomics-Based Ameliorative Strategies
In addition to elucidating the cause and consequences of
transcriptional dysregulation in HD, transcriptomics analysis
has been used to test the efficacy of ameliorative strategies that
directly or indirectly restore the altered activity of gene ex-
pression regulators. In this section, the genome-wide studies
aimed at analyzing the transcriptional changes associated with
amelioration by genetic and pharmacological means are
summarized.
Gene Profiling Analysis for the Design of Ameliorative
Strategies
Transcriptional profiles can be considered to be intermediate
outcomes between the origin of the pathology (e.g., mutation
of the Htt gene in HD) and the phenotypical manifestation at
the level of behavior. Brain transcriptomes have the potential
to record experiences, plasticity events, perturbation episodes,
and medical interventions either in a transient or, as often
occurs with neuropathologies, in a permanent manner. In the
case of HD, the accumulation of gene expression rearrange-
ments involves direct regulatory mechanisms, cytosolic pro-
cesses that affect the fine-tuned activation of downstream
signaling pathways converging in the nucleus, and the tran-
scriptional homeostatic responses to minimize damage, which
together constitute the “disease signature.” In the same way, it
is possible to define the “ameliorative signature” as the frac-
tion of genes which expression is restored by a particular
treatment [148, 149]. This signature is also useful in the search
for biomarkers for monitoring progression deceleration. In
theory, the analysis of HD transcriptomics can (i) provide a
quantifiable output of the suitability of preclinical therapeu-
tics, (ii) propose novel strategies based on meta-analyses of
concurrent genome-wide data, and (iii) identify the players
involved in amelioration, to finally obtain invaluable insights
for the improvement and design of ameliorative strategies.
Evaluation of mHtt Targeting
Long-term silencing of mHtt by RNA interference (based on
either small hairpin RNA or artificial miRNAs) represents a
promising strategy to alleviate the gain-of-function effects in
patients [150]. To reach an optimal balance between efficacy
and safety, the effect of nonallele-specific interfering RNAs
has been studied. In two different designs [151, 152], nonspe-
cific targeting of Htt proved to be beneficial in vivo despite
knocking down the endogenous wild-type variant; tolerance
to wild-type Htt silencing is not exclusive to rodents and has
also been described in adult rhesus macaques [153]. Of note,
there were transcriptional changes caused by the delivery of
these interfering RNAs in the control striatum. This
transcriptomic effect, associated with wild-type Htt reduction,
was partially consistent with diverse knockdown scenarios in
HD models [36, 38, 154, 155], thus confirming the loss-of-
function signature in HD. A third study minimized the toxic
side effects of off-targeting silencing (unintended silencing of
unrelated genes) by focusing the design of interference RNAs
on the seed sequence that recognizes the Htt transcript. A
screening complemented with microarray analysis in tran-
siently transfected HEK293 cells identified two small RNA
candidates that met the criteria of minimal off-targeting (very
low number of altered transcripts) and high efficacy (large
reduction in the Htt transcript). Subsequent long-term assess-
ments demonstrated a lack of overt neurotoxicity in vivo
[156].
Modulators of polyQ-Induced Toxicity
One of the main advantages of proliferative cellular-based
models is the ability to conduct large systematic and unbiased
screenings. Regarding mHtt-expressing cells, this approach
allows the identification of both tractable intracellular path-
ways and novel compounds by investigating the reversal of
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polyQ-induced cell death. This information would be useful
for the posterior design of therapeutics in animal models.
Target candidates for amelioration can be determined within
the HD signature. Thus, overexpression may potentially re-
store cellular deficits (e.g., glucose metabolism and oxidative
stress) [12] and potentiate the so-called homeostatic response;
for example, a significant proportion of the upregulated genes
in stably transfected cell lines were able to promote the clear-
ance of mHtt and slow its accumulation in subsequent over-
expression experiments [157]. Alternatively, the screening of
a library of compounds allows for the proposal of mechanisms
of death prevention by using transcriptomics information as
an unbiased starting point. This is the case of the microtubule
destabilizer podophyllotoxin, which enhances survival
through the activation of the ERK pathway via the
microtubule-associated Rho/Rac activator, guanine nucleotide
exchange factor H1 (ARHGEF2/GEF-H1) [158].
Combined Pharmacological Treatments
Cocktail preparations may have synergic actions in improving
cognitive and motor symptoms. This is the basis for the triple
treatment used in the fast progressive R6/2 transgenic model.
This treatment aims to increase neurotransmitter levels and
mitigate mitochondrial dysfunction simultaneously, using the
acetylcholine esterase inhibitor tacrine, the monoamine oxi-
dase A inhibitor moclobemide, and creatine [159]. Interest-
ingly, this combined treatment alleviates the HD phenotype
more successfully than single-drug administration and glob-
ally reverses transcriptional changes: nearly 50 % of the
profile returned to normal levels.
Environmental Enrichment
Several reports indicated that the housing conditions of HD
mice have an impact on disease progression and opened the
possibility for occupational-related therapies. Thus, animals
maintained under environmental enrichment (i.e., with oppor-
tunities for frequent exploration, interaction with novel ob-
jects, climbing, and other voluntary exercise in a changing
environment) exhibited phenotypical amelioration and an ex-
tended survival rate [160–163]. Although long-term environ-
mental enrichment is known to rescue deficits in genes, such
as BDNF, the cannabinoid receptor 1, and the striatal marker
dopamine and cAMP-regulated neuronal phosphoprotein
(DARPP-32/Ppp1r1b)) [164], a global transcriptomic analysis
failed to fully associate the effects of enrichment with any
change in gene expression and concluded that the beneficial
effects were due to a reduction in aggregate load [165]. In
contrast, the environmental enrichment paradigm was report-
ed to cause significant transcriptional rearrangement in other
studies [166–168], probably indicating the need for standard
procedures.
Restoration of BDNF Levels
The meta-analysis of datasets from diverse sources, as
discussed in the “Genome-Wide Approaches to Link Tran-
scriptional Dysregulation and Altered Regulator Activities”
section, can be extended to other gene products not directly
related to expression regulation. In cases where the overlap is
significant, it may be feasible to investigate the ability of
available drugs to modulate newly identified targets or their
associated pathways. This principle is well represented by the
prosurvival factor BDNF. Depletion of wild-type Htt not only
leads to the transcriptional repression of the Bdnf locus but
also interferes with the trafficking of BDNF-containing vesi-
cles. Overall, cortical supply of this neurotrophic factor to the
striatum becomes impaired in HD [169]. Cross-comparison
between HD and BDNF knockout datasets from the striatum
revealed their high similarity, indicating the importance of
BDNF deficits in this pathology. However, the concordance
of BDNF-deficient profiles was higher in HD caudate patients
compared with the transgenic R6/2 model, in agreement with
a primary loss-of-function mechanism to alter BDNF levels.
In any case, the ameliorative potential of BDNF-based thera-
pies was demonstrated in HD animal models [170, 171],
although a corresponding reversal of the HD transcriptome
remains to be tested.
Targeting Expression Regulators
Because transcriptional dysregulation is an early event in HD,
directly targeting expression regulators may have an influence
on the disruption of other processes in the neuron. This idea is
supported by numerous experiments that rescued altered tran-
scriptional activities by either overexpressing activators or
knocking down repressors, thus restoring the expression
levels of selected target genes and improving the well-being
of sick animals and unhealthy cells. Interestingly, augmenta-
tion of the expression levels of wild-type Htt at the transcrip-
tional regulatory level has been proposed to restore its phys-
iological roles, as exemplified by homeodomain transcription
factor Engrailed, which prevents mHtt aggregation and neu-
rodegeneration by activation of endogenous Htt in a
Drosophila model of HD [172]. The next section summarizes
ameliorative strategies that have been tested in HD cellular
and animal models to correct aberrant nuclear activities and
have been monitored by gene expression profiling.
HDAC Inhibitors (HDACi)
The drugs belonging to different chemical families that are
capable of inhibiting deacetylase activity are generally re-
ferred to as HDACi. Therefore, these drugs counterbalance
possible deficits in acetyltransferase activity and restore the
acetylation levels of histones and other nuclear proteins. This
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is the main proposed mechanism underlying the
transcriptional-dependent amelioration of pathophenotypical
traits observed in HD models (see Valor and Guiretti [76] for
further details). In an attempt to identify the target genes
responsible for such amelioration in HD, Ferrante and co-
workers conducted a series of microarray studies in mouse
models chronically treated with butyrate compounds. The
correction of the HD signature was extremely limited [135,
173]; however this correction can involve a few highly rele-
vant candidates for the mouse, including proapoptotic
caspase-9 [135]. Alternatively, HDACi can exert their effects
through the indirect activation of compensatory mechanisms.
This is the case of the inhibition of the cytosolic sirtuin 2 (Sirt2),
which failed to globally correct transcriptional dysregulation but
reduced the shuttling of sterol regulatory element binding protein
2 (SREBP-2) to the nucleus, promoting downregulation of sterol
biosynthesis genes independently of the mHtt expression. Thus,
Sirt2 inhibition conferred neuroprotection by modulating choles-
terol homeostasis [174]. In terms of HD signature reversal, the
use of HDACi 4b was more successful. This treatment defini-
tively normalized the expression of one third of deregulated
genes, with a total trend toward normalization of more than
80 % of altered genes in the cortex, striatum, and cerebellum in
transgenic R6/2 mice [56]. Importantly, HDACi treatment may
have an impact, although subtle, on peripheral biomarkers [50,
51] that can bemonitored for amelioration during treatments. It is
worth noting that the acetylated status of hundreds of proteins
can be influenced by HDAC inhibition [175]. Therefore amelio-
rative strategies based on the use of HDACis are beneficial due to
their combined effects on histone and nonhistone substrates,
either nuclear or cytosolic.
Anthracyclines
These drugs with antibiotic and anticancer properties have
different mechanisms of action that involve interaction with
the DNA, including histone eviction [176]. In the case of the
two anthracyclines tested in pharmacological therapy of HD,
mithramycin and chromomycin, binding to the minor groove
of DNA promotes the displacement of GC-rich binding regu-
lators, such as the Sp1 family members, with important con-
sequences on restoring the imbalance between histone meth-
ylation and acetylation [76]. Biochemical and phenotypical
amelioration was accompanied by the correction of a relative-
ly small number of genes, including DARPP-32 and calcium/
calmodulin-dependent protein kinase Camk1g, as determined
by microarray analysis [133].
Activators of Heat Shock Proteins (HSPs)
Due to the protective actions of HSPs in the management of
misfolded and aggregated proteins, it is not surprising that
ameliorative strategies aimed at enhancing HSP activity
reduced polyQ-induced toxicity in parallel with intracellular
mHtt aggregate load. This enhancement can be achieved by
using chemical inhibitors of the ATP binding of HSP90,
including the antibiotic geldanamycin and its derivatives,
17-AAG and 17-DMAG, thus affecting the repressive actions
on HSF1 expression, the master regulator of HSPs [177].
Bates and colleagues explored the beneficial effects of the
HSP90 inhibitor NVP-HSP990 in the R6/2 model [119]. This
study is an interesting example of dissecting the failure of a
long-term ameliorative strategy to extract meaningful conclu-
sions for further therapeutical design. Although this treatment
demonstrated an improvement in the rotarod task performance
and aggregate load reduction in the early stage of the pathol-
ogy, this amelioration was later lost at the same time that the
gene induction of HSPs was impaired, as observed by micro-
array analyses. This impairment was explained on the basis of
a reduction in the binding of HSF1 at HSP gene promoters,
where histone H4 was found to be hypoacetylated [119].
ChIP-seq analysis in a Drosophila cell line demonstrated that
histone acetylation determines the inducible binding of the fly
HSF1 ortholog [178]. Therefore, reversing histone acetylation
deficits (e.g., by HDACi treatment) may extend the activation
of HSPs in the treatment of HD.
REST Inhibitors
Screening libraries of compounds may identify novel drugs
that modulate the activity of deregulated expression regulators
in HD. In a structural-based approach, one screen retrieved
quinolone-like compound 91, which reduced REST occupan-
cy at the BDNF locus by reducing the activity of the REST-
interacting partner Sin3b [179]. In another screen, several
derivatives of benzoimidazole-5-carboxamide and pyrazole
propionamide were able to reduce the luciferase activity driv-
en by REST-binding motifs [180]. One of these derivatives
(X5050) exerted its action by promoting REST protein deg-
radationwithout interfering with its DNA binding or transcript
levels. Confirmatory microarray analysis of neuronal stem
cells treated with X5050 demonstrated a transcriptomic effect
in which upregulation was predominantly enriched in neuro-
nal genes predicted to be controlled by REST, with a concom-
itant downregulation of chromatin-related genes. As a valida-
tion of the activity of X5050 in a HD context, the expression
of neuronal markers was increased after treatment in a stem
cell model of HD and in chemically lesioned striata [180].
Final Remarks
Aberrant expanded polyQ stretches, independently of the gene
context, may affect similar regulatory mechanisms that should
be reflected at the gene expression level. Thus, models for
other polyQ disorders, such as dentatorubropallidoluysian
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atrophy (DRPLA), spinobulbar muscular atrophy (SBMA) or
Kennedy disease, and spinocerebellar ataxia types 1 and 7
(SCA1, SCA7), share altered transcriptional genes with HD
signatures [22, 26, 30, 181, 182].
Similarities can be extended to other neurodegenerative
disorders that exhibit common characteristic hallmarks, such
as channel-mediated cytotoxicity, mitochondrial dysfunction,
intracellular trafficking, and deposition of misfolded proteins
may influence and be influenced by shared transcriptional and
epigenetic regulatory mechanisms. Therefore, it is not surpris-
ing that similar ameliorative strategies in HD are also appli-
cable in other neuropathologies. For example, HDACi have
been tested in cognitive pathologies, including neurodegener-
ative disorders and intellectual disabilities: HD, AD,
Parkinson’s disease (PD), stroke, traumatic brain injury,
amyotrophic lateral sclerosis (ALS), Friedrich ataxia, SBMA,
DRLA, and Rubinstein-Taybi syndrome [76, 183, 184].
Anthracyclines have been used in ischemia and oxidative
stress [185, 186], and induction of HSPs has been tested in
neurodegenerative conditions with a notable presence of pro-
tein aggregation (AD, PD, ALS, Prion disease, etc.) [187].
Vice versa, useful insight for HD research can be obtained
from transcriptomics analysis performed in models for other
disorders, such as the effects of BDNF and environmental
enrichment in AD [167, 188]. Although still very preliminary,
meta-analyses of gene profiles from different neurodegenera-
tive models have been conducted to identify common tracta-
ble pathways, such as the immune response and insulin-
related pathways and synaptic-related functions [189–191]
to put some examples. However, we need to learn more about
HD transcriptional dysregulation, and analytical and experi-
mental procedures should be standardized for better compar-
isons between conditions. For example, a refinement of the
gene profiling studies of HD models at the temporal and
cellular resolution is necessary. The use of LCM for the
isolation of specific subpopulations, such as the cortical neu-
rons of layer 5 [192] and Purkinje neurons [181], and the
generation of animal models with highly specific expression
patterns of the mHtt transgene [57], produce cellular-specific
HD signatures with improved sensitivity over whole tissues.
Techniques such as fluorescent-activated cell sorting (FACS)
or translating ribosomal affinity purification (TRAP) can be
useful alternatives. In any case, novel technologies, such as
next-generation sequencing, are able to unravel unsuspected
features (novel RNA species) or complex relationships (as
occurs between transcriptional dysregulation and epigenetic
marks). Moreover, the compilation and integration of
genome-wide data, including transcriptomics, proteomics,
epigenomics, and genomic occupancy, will be necessary for
the full comprehension of the biological implications of tran-
scriptional dysregulation in HD and to explore the full poten-
tial of genome-wide approaches in the design of improved
therapeutics.
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